1. Home
  2. ABUS vs HBNC Comparison

ABUS vs HBNC Comparison

Compare ABUS & HBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Logo Horizon Bancorp Inc.

HBNC

Horizon Bancorp Inc.

HOLD

Current Price

$18.53

Market Cap

944.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
HBNC
Founded
2005
1873
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
848.8M
944.0M
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
ABUS
HBNC
Price
$4.56
$18.53
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$5.00
$21.00
AVG Volume (30 Days)
1.2M
218.7K
Earning Date
05-14-2026
04-22-2026
Dividend Yield
N/A
3.57%
EPS Growth
55.26
N/A
EPS
0.87
0.51
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$239.71
$5.52
P/E Ratio
$5.28
$36.12
Revenue Growth
128.21
N/A
52 Week Low
$3.04
$14.38
52 Week High
$5.10
$19.07

Technical Indicators

Market Signals
Indicator
ABUS
HBNC
Relative Strength Index (RSI) 57.10 58.32
Support Level $4.16 $17.07
Resistance Level $4.60 $18.84
Average True Range (ATR) 0.18 0.38
MACD 0.04 0.01
Stochastic Oscillator 67.81 76.52

Price Performance

Historical Comparison
ABUS
HBNC

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About HBNC Horizon Bancorp Inc.

Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.

Share on Social Networks: